Infection Control & Hospital Epidemiology
was conducted in a single healthcare system, the results may not be generalizable to other dissimilar institutions. In conclusion, the results of our study demonstrate that
community-onset ESC-R EB UTIs are associated with increased odds of clinical failure and IIAT. Also, IIAT is in part, but not entirely, responsible for the worse outcomes associated with ESC-R EB UTIs. Further studies are needed to determine those patients who are at high risk for drug-resistant UTIs so that urine cultures are collected and appropriate antibiotics are prescribed promptly.
Acknowledgments. None.
Financial support. This work was supported by the Agency for Healthcare Research and Quality (grant no. R18-HS020002 to E.L.), by the National Institutes of Health (grant nos. K24-AI080942 to E.L. and K01-AI103028 to J.H.H.), by the Centers for Disease Control Cooperative Agreement Epicenters for the Prevention of Healthcare Associated Infections (grant no. FOA#CK16- 004 to E.L.), and by the Antibacterial Resistance Leadership Group (grant no. 5 UM 1AI104681-05 with a subaward fellowship grant to J.A.A.).
Conflict of interest. All authors report no conflicts of interest relevant to this article.
Supplementary material. To view supplementary material for this article, please visit
https://doi.org/10.1017/ice.2018.254
References
1. Pitout JD, Hanson ND, Church DL, Laupland KB. Population-based laboratory surveillance for Escherichia coli–producing extended-spectrum beta-lactamases: importance of community isolates with blaCTX-Mgenes. Clin Infect Dis 2004;38:1736–1741.
2. Canton R, Novais A, Valverde A, et al. Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect 2008;14 Suppl 1:144–153.
3. Rodriguez-Bano J, Navarro MD, Romero L, et al. Bacteremia due to extended-spectrum beta-lactamase–producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006;43:1407–1414.
4. Ben-Ami R, Schwaber MJ, Navon-Venezia S, et al. Influx of extended- spectrum beta-lactamase–producing enterobacteriaceae into the hospital. Clin Infect Dis 2006;42:925–934.
5. Simonsen L, Conn LA, Pinner RW, Teutsch S. Trends in infectious disease hospitalizations in the United States, 1980–1994. Arch Intern Med 1998;158:1923–1928.
6. Talan DA, Krishnadasan A, Abrahamian FM, Stamm WE, Moran GJ, EMERGEncy IDNET Study Group. Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escheri- chia coli infection among emergency department patients with pyelone- phritis. Clin Infect Dis 2008;47:1150–1158.
7. Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005;56:52–59.
8. Calbo E, Romani V, Xercavins M, et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended- spectrum beta-lactamases. J Antimicrob Chemother 2006;57:780–783.
9. Colodner R, Rock W, Chazan B, et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 2004;23:163–167.
1435
10. Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM. Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase–producing
infections in Thailand: a case-case-control study. Am J Infect Control 2007;35:606–612.
11. Apisarnthanarak A, Kiratisin P, Mundy LM. Predictors of mortality from community-onset bloodstream infections due to extended-spectrum beta- lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2008;29:671–674.
12. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended- spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001;32:1162–1171.
13. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae. Agents Chemother 2006;50:1257–1262.
Antimicrob
14. Yang YS, Ku CH, Lin JC, et al. Impact of Extended-spectrum beta- lactamase-producing Escherichia coli and Klebsiella pneumoniae on the outcome of community-onset bacteremic urinary tract infections. J Microbiol Immunol Infect 2010;43:194–199.
15. Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL)–producing E. coli compared to non–ESBL-producing E. coli. J Infect 2007;55:254–259.
16. Kang CI, Song JH, Chung DR, et al. Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta- lactamase-producing Escherichia coli. Int J Antimicrob Agents 2010;36:284–287.
17. MacVane SH, Tuttle LO, Nicolau DP. Impact of extended-spectrum beta- lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection. J Hosp Med 2014;9:232–238.
18. Esteve-Palau E, Solande G, Sanchez F, et al. Clinical and economic impact of urinary tract infections caused by ESBL-producing Escherichia coli requiring hospitalization: a matched cohort study. J Infect 2015; 71:667–674.
19. CDC/NHSN. CDC/NHSN Surveillance definitions for specific types of infections. Centers for Disease Control and Prevention website. http://
www.cdc.gov/nhsn/PDFs/pscManual/17pscNosInfDef_current.pdf. Pub- lished 2016. Accessed September 20, 2018.
20. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, M100-S20. CLSI; 2010.
21. Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Bilker WB, Lautenbach E. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase–producing entero- bacteriaceae: variability by site of infection. Arch Intern Med 2005;165:1375–1380.
22. Tumbarello M, Sali M, Trecarichi EM, et al. Bloodstream infections caused by extended-spectrum-beta-lactamase–producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrob Agents Chemother 2008;52:3244–3252.
23. Tumbarello M, Spanu T, Di Bidino R, et al. Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum- beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother 2010;54:4085–4091.
24. Lindberg F, Westman L, Normark S. Regulatory components in Citrobacter freundii ampC beta-lactamase induction. Proc Natl Acad Sci USA 1985;82:4620–4624.
25. Minnaganti VR, Cunha BA. Infections associated with uremia and dialysis. Infect Dis Clin North Am 2001;15:406.
Escherichia coli
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124
